Logo image of FBLG

FIBROBIOLOGICS INC (FBLG) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:FBLG - US31573L1052 - Common Stock

0.249 USD
+0.01 (+5.55%)
Last: 12/26/2025, 8:00:02 PM
0.2365 USD
-0.01 (-5.02%)
After Hours: 12/26/2025, 8:00:02 PM

FBLG Key Statistics, Chart & Performance

Key Statistics
Market Cap17.40M
Revenue(TTM)N/A
Net Income(TTM)-18.50M
Shares69.86M
Float61.67M
52 Week High2.39
52 Week Low0.22
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.48
PEN/A
Fwd PEN/A
Earnings (Next)03-30 2026-03-30
IPO2024-01-31
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


FBLG short term performance overview.The bars show the price performance of FBLG in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40 -50

FBLG long term performance overview.The bars show the price performance of FBLG in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of FBLG is 0.249 USD. In the past month the price decreased by -8.49%. In the past year, price decreased by -89.45%.

FIBROBIOLOGICS INC / FBLG Daily stock chart

FBLG Latest News, Press Relases and Analysis

FBLG Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 24.34 406.46B
AMGN AMGEN INC 15.22 179.28B
GILD GILEAD SCIENCES INC 15.23 154.71B
VRTX VERTEX PHARMACEUTICALS INC 26.66 117.45B
REGN REGENERON PHARMACEUTICALS 17.44 82.50B
ALNY ALNYLAM PHARMACEUTICALS INC 785.47 52.92B
INSM INSMED INC N/A 37.94B
NTRA NATERA INC N/A 32.26B
BIIB BIOGEN INC 10.58 25.98B
UTHR UNITED THERAPEUTICS CORP 19.22 21.84B
INCY INCYTE CORP 15.59 19.65B
EXAS EXACT SCIENCES CORP N/A 19.27B

About FBLG

Company Profile

FBLG logo image FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Company Info

FIBROBIOLOGICS INC

455 E. Medical Center Blvd, Suite 300

Houston TEXAS US

Employees: 13

FBLG Company Website

FBLG Investor Relations

Phone: 12816715150

FIBROBIOLOGICS INC / FBLG FAQ

Can you describe the business of FIBROBIOLOGICS INC?

FibroBiologics, Inc. engages in the development and commercialization of cell therapies. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2024-01-31. The firm is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). The company is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. The company is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.


Can you provide the latest stock price for FIBROBIOLOGICS INC?

The current stock price of FBLG is 0.249 USD. The price increased by 5.55% in the last trading session.


Does FBLG stock pay dividends?

FBLG does not pay a dividend.


What is the ChartMill rating of FIBROBIOLOGICS INC stock?

FBLG has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Can you provide the upcoming earnings date for FIBROBIOLOGICS INC?

FIBROBIOLOGICS INC (FBLG) will report earnings on 2026-03-30.


Can you provide the short interest for FBLG stock?

The outstanding short interest for FIBROBIOLOGICS INC (FBLG) is 2.25% of its float.


FBLG Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

FBLG Financial Highlights

Over the last trailing twelve months FBLG reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS increased by 45.73% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -211.59%
ROE -14800.8%
Debt/Equity 36.58
Chartmill High Growth Momentum
EPS Q2Q%-1200%
Sales Q2Q%N/A
EPS 1Y (TTM)45.73%
Revenue 1Y (TTM)N/A

FBLG Forecast & Estimates


Analysts
Analysts82.22
Price TargetN/A
EPS Next Y-39.21%
Revenue Next YearN/A

FBLG Ownership

Ownership
Inst Owners7.73%
Ins Owners8.66%
Short Float %2.25%
Short Ratio0.96